ArticleGlobal heart2025
Global Guidance for Dyslipidaemia Management in Adults: A Scoping Review.
Article in Global heart, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Objective: Dyslipidaemia is a leading preventable cause of global cardiovascular disease (CVD) burden, responsible for over four million deaths each year (1). A scoping review took a worldwide perspective and assessed recent World Health Organization (WHO) guidance documents, other national or regional guidelines, and randomized controlled trial evidence supporting dyslipidaemia management best practices. Methods: Review of WHO guidance documents included aspects of dyslipidaemia management, but none provided a detailed and comprehensive approach. Of 11 non-WHO national or regional dyslipidaemia guidelines, nine met pre-defined inclusion criteria and were reviewed in depth. Structured electronic searches of MEDLINE found 27 systematic reviews of randomized clinical trials supporting dyslipidaemia management guideline priority topics. Findings: This scoping review found overall consistency in the recommendations of regional and national dyslipidaemia guideline recommendations. Guidelines varied in terms of approach to assessing patient CVD risk and recommendations to treat with non-statin lipid-lowering therapy (LLT). Robust randomized trial evidence supports that a dyslipidaemia management guideline focuses on priority areas including approach to patient selection for LLT efficacy and safety, selection of initial LLT drugs and dose intensity, timing of LLT monitoring, and LLT management in specific high-risk groups (familial hypercholesterolemia, diabetes, chronic kidney disease, HIV and other inflammatory diseases, and older adults). Few regional or national guidelines provided practical implementation recommendations or cost-effectiveness assessments; less clinical trial evidence was found for the priority topic of equitable treatment. Conclusion: Taking a global perspective, this scoping review describes the scope and depth of the current evidence base informing best practice management of dyslipidaemia for the primary and secondary prevention of CVD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.